British researchers have found that MRI scans alone can accurately diagnose prostate cancer in some instances, a development that could spare thousands of men from invasive biopsies. The study suggests that MRI could join other imaging techniques used to diagnose cancers like those of the kidney and liver without the need for tissue samples.
Prostate cancer is the most common cancer affecting men in the UK, with nearly 58,000 diagnoses annually. Current National Health Service (NHS) guidelines recommend an MRI scan before a biopsy to determine if the invasive procedure is necessary, given the small risks of infection and bleeding associated with biopsies. However, limitations in scanner capacity and staffing shortages often lead to men being sent directly for biopsies.
Dr. Alex Kirkham, a consultant radiologist at University College London Hospital, noted that patients are already treated for several other cancers based on imaging alone. "This study suggests prostate cancer could, in some cases, join that list," he said, adding that further research could confirm findings that would help thousands of men avoid a "risky and uncomfortable" procedure.
The study, published in the European Journal of Radiology, analyzed scans from 880 men suspected of having prostate cancer who attended a hospital clinic. All participants underwent a prostate MRI and a PSA blood test. Radiologists assessed the certainty of cancer presence based on the scans. The research found that when doctors were 99% certain of a cancer diagnosis from the MRI, biopsies confirmed the presence of cancer in every case. The scans also proved highly accurate in identifying significant cancers even at slightly lower confidence levels.
The researchers concluded that in a specific group of patients, MRI findings can indicate cancer with near certainty, potentially allowing for treatment without a biopsy. This could lead to faster treatment and reduced patient discomfort. Dr. Kirkham expressed surprise at the confidence with which some scans could be interpreted, even with small tumors or unremarkable PSA levels, indicating that certain prostate cancers have a distinct appearance on MRI.
Wait times for biopsies and their results are a common target breach across all cancer pathways within the NHS. For suspected prostate cancer, guidelines stipulate referral for MRI and biopsy within seven days of an urgent GP referral, but capacity issues often extend these timelines.
Dr. Mark Emberton, a consultant urologist at UCLH, highlighted the urgency of finding faster, more reliable diagnostic methods, especially as global prostate cancer cases are projected to double by 2040 due to aging populations. "Together, these pressures make faster, more reliable ways of diagnosing prostate cancer an urgent priority," he stated.
Earlier this year, the National Screening Committee rejected proposals for a nationwide PSA screening program, citing concerns about potential over-diagnosis and over-treatment, which could lead to side effects like impotence and incontinence for men whose tumors might not have caused issues during their lifetime. Currently, screening is offered only to men who request a test or are identified as high-risk.